Maciej Jasinski’s Post

I’m pleased to announce that I’ll be presenting at BIOVIA Live! 🎤 Join me as I explore the groundbreaking deep learning and AI-based tools within Discovery Studio that are revolutionizing biologics research. In my talk, I’ll highlight: 🔹 OpenFold and AlphaFold Multimer for precise protein structure prediction 🔹 RFDiffusion for designing innovative protein scaffolds 🔹 Protein MPNN for efficient sequence optimization Additionally, I’ll showcase how our AI-enhanced solutions for antibody humanization are streamlining therapeutic design, and the deep learning-driven paratope prediction that provides unparalleled accuracy in epitope identification. These advancements are empowering researchers with unprecedented capabilities to accelerate and refine the biologics development process. I can’t wait to share insights and explore the future of biologics research together! See you there! 🚀 #BIOVIALive #Biologics #AI #DeepLearning #ResearchInnovation

Recently I read an article published on BioPharm International, Volume 35, Number 11, November 2022, Pages: 10-15 by Cynthia A. Challener, PhD. I would like to put my thoughts into a discussion with like-minded people. 𝐓𝐡𝐞 𝐅𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐁𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬: 𝐍𝐞𝐰 𝐌𝐨𝐝𝐚𝐥𝐢𝐭𝐢𝐞𝐬, 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬𝐞𝐝 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞, 𝐚𝐧𝐝 𝐀𝐈 𝐢𝐧 𝐏𝐫𝐨𝐜𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 As highlighted in the recent article by the Author, the increasing molecular diversity of new drug modalities such as 𝐦𝐑𝐍𝐀, 𝐠𝐞𝐧𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬, 𝐚𝐧𝐝 𝐛𝐢𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐚𝐧𝐭𝐢𝐛𝐨𝐝𝐢𝐞𝐬 is driving a need for innovation in 𝐩𝐫𝐨𝐜𝐞𝐬𝐬 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐜𝐨𝐧𝐭𝐫𝐨𝐥 𝐬𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬. The complexity of these therapies, from process automation challenges to raw material supply chain constraints, presents exciting opportunities for innovation. With 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 becoming a key focus, it’s clear that new technologies, including 𝐀𝐈-𝐝𝐫𝐢𝐯𝐞𝐧 𝐩𝐫𝐨𝐜𝐞𝐬𝐬 𝐦𝐨𝐝𝐞𝐥𝐥𝐢𝐧𝐠 𝐚𝐧𝐝 𝐚𝐮𝐭𝐨𝐦𝐚𝐭𝐢𝐨𝐧, are critical to improving the efficiency of biologics development. How can we ensure that AI tools, 𝐏𝐫𝐨𝐜𝐞𝐬𝐬 𝐀𝐧𝐚𝐥𝐲𝐭𝐢𝐜𝐚𝐥 𝐓𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 (𝐏𝐀𝐓), and digital simulations evolve to keep pace with the rapid development of these new modalities? I'd love to hear your thoughts on: 1. How AI can streamline 𝐛𝐢𝐨𝐥𝐨𝐠𝐢𝐜𝐬 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐩𝐫𝐨𝐜𝐞𝐬𝐬𝐞𝐬. 2. The role of 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬𝐞𝐝 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 in shaping future development. 3. Ways to tackle supply chain and process complexity for 𝐞𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐭𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬. Let's discuss how we can continue to innovate in biologics to deliver safe, effective therapies to patients faster. #Biologics #NewModalities #AIinHealthcare #PersonalisedMedicine #ProcessDevelopment #BiotechInnovation #Pharma

Revolutionizing Drug Discovery: 15 AI Companies to Watch in 2024 #pharma #AI #drugs 1. Atomwise: Revolutionizing Virtual Screening 2. BenevolentAI: AI-Driven Drug Discovery 3. Insilico Medicine: Aging Research and Drug Discovery 4. Recursion Pharmaceuticals: AI-Powered Drug Repurposing 5. Molecule AI: AI-Powered Drug Design Platform 6. Numerate: Precision Chemistry with AI 7. TwoXAR ( ARIA ): Accelerating Preclinical Development 8. Deep Genomics: AI for Genomic Medicine 9. Recce Pharmaceuticals: AI-Enhanced Antibiotics  10. Biosymetrics: Integrated Data Analytics  11. Ardigen: Immunotherapy Advancements with AI 12. Cyclica: Polypharmacology and Network Pharmacology 13. Healx: Rare Disease Drug Discovery 14. BioXcel Therapeutics: Pharma AI for Drug Development 15. Strateos: Robotic Cloud Labs for Drug Discovery

High-throughput Omics technologies are needed to solve challenges in protein science and biotherapeutic development, including antibody discovery and engineering, characterization of biologics, and more. SPOC is the world’s first highly multiplexed kinetic proteomic biosensor. By automating in situ production and capture-purification of fully-folded functional protein arrays on biosensors, SPOC can simultaneously analyze up to 1000 unique proteins on a single SPR sensor, making SPOC the only proteomics platform to provide qualitative, quantitative, and kinetic data at scale. Kinetic data from SPOC uniquely identifies on- and off-target interactions (including high-off rate binders), facilitates lead candidate identification, informs on therapeutic design (including for AI platforms), and more. With multiple applications, there is sure to be a SPOC biosensor solution for your research. Come see our PepTalk presentation on Jan 19th, presented by Dr. Chidozie Agu, PhD, highlighting our recent data in: ▪ AI-designed mAb characterization ▪ Infectious disease serology for vaccine target discovery ▪ Using kinetics to monitor mutation-driven drug escape for mAbs https://lnkd.in/gP3kGX3V #spoc #spocproteomics #highthroughput #biotherapeutics #biologics #antibodydiscovery #omics #chipeptalk

Preclinical research is a term that refers to, simply, any research about a drug or treatment for a disease that occurs before it is tested by human volunteers. Learn more about preclinical research here: https://lnkd.in/eycdvFfX

Short-term impact of Biotech and CROs like ourselves. See the pdf below for full details. Short term future looks positive. The biotech landscape is swiftly evolving, with a recent survey of 150 emerging biotech executives, conducted by BioPharma Dive and Cytiva, revealing keen insights into the future of CRO and CDMO partnerships. Amidst complex challenges like manufacturing intricacies and market pressures, there's a clear call for enhanced outsourcing relationships. Key findings include a notable drive towards advanced therapies, such as cell and gene therapies and monoclonal antibodies, yet there's a marked gap in confidence regarding manufacturing capacity for 2024. This scenario presents an opportunity for CROs and CDMOs to step up with solutions like process automation and modular facilities. Market and data concerns, including rising interest rates and labor shortages, underscore the growing importance of strategic outsourcing partnerships with companies such as ourselves. Biotechs highly value data analytics, regulatory expertise, and competitive pricing in their partners. Although satisfaction with current partners is high, there's a universal appetite for improvements in time efficiency and cost transparency. The survey underlines a positive moment for CROs and CDMOs to align closely with biotech needs, offering a chance to differentiate and cement their value in facilitating biotech advancements. For more insights, visit Cytiva's Biopharma Dive. #BiotechTrends #CROPartnerships #CDMOPartnerships #OutsourcingEvolution #InnovationInBiotech #RegulatoryExpertise #DataAnalyticsInBiotech

Achieving In Vivo PoC from the First Shot: Selectively Targeting 6 Ion Channel Isoforms We’re excited to share a case study in which we developed highly selective inhibitors targeting one specific ion channel isoform among six closely related others, each sharing at over 90% similarity in binding pocket. Our team achieved remarkable selectivity, leading to in vivo proof of concept (PoC) from the first shot, demonstrating significant potency and the absence of toxicity. This success was facilitated by our dedicated workflow designed specifically for targeting membrane proteins and highly similar targets such as isoforms, allele variants, and mutants. Background & Objectives: ◾ Our objective was to develop inhibitors that selectively target a specific ion channel isoform and specifically to the open channel conformation.  ◾ Our platform allows comprehensive modeling of the membrane targets by generating representative ensembles of their conformations in an explicit membrane environment including specific lipid composition elucidated by lipidomics and accounting for the membrane leaflets asymmetry in lipid and cholesterol content. ◾ The primary challenge was identifying the optimal binding pocket for selectivity, especially given the need to differentiate between similar isoforms and the channel's functional states. ◾ Achieving in vivo PoC was essential to confirm therapeutic efficacy.   We conducted extensive virtual screening of 5 million compounds, followed by molecular dynamics simulations and pharmacophore modeling to refine the selection of highly selective inhibitors. These top candidates were then validated through in vivo testing, confirming their potency and selectivity. Key Highlights: ◾ 40% hit rate: Out of 5 million compounds, 291 were identified as active hits ◾ 5 selective compounds against all isoforms: The top compound exhibited 3.16 times selectivity, with the top 5 showing up to 5 times selectivity across all isoforms, including effective targeting of both open and closed channel states. ◾ Significant In Vivo Activity: 3 compounds demonstrated substantial in vivo activity, including one that was highly potent. ◾ Novelty: Several compounds represent entirely new classes of chemical entities, showcasing the potential to design novel compounds. This case study demonstrates the successful application of our platform in achieving in vivo proof of concept from the first attempt, setting a new standard in the development of highly selective and potent treatments. Read the full case study here: https://lnkd.in/eWwWY-mJ Stay tuned for more developments from Receptor.AI! #DrugDiscovery #AI #IonChannels #Selectivity #DrugSafety #MembraneTargets #Biotech #PharmaInnovation

PEGS, held this week in Boston, is the top resource for protein engineering updates, networking, collaboration, and learning. Machines and AI in biologics continue to be a hot topic in the areas of drug development, protein and antibody engineering, immunotherapy, immunogenicity, expression platforms, and multi-specific antibodies. From design to product, the key is to optimize the process (evaluate back and forth), and it is exciting to see that Gator Bio BLI technology has been widely used in this process. #AI #PEGS #Protein #Antibody #Engineering #Expression #Gator #BLI

We're excited to announce the launch of our latest report on the life science sector, based on insights from our second Life Science Global Survey! This comprehensive overview explores the rapid evolution and challenges in the industry, including advancements in gene and cell therapies, biologics and vaccines. Key concerns from our survey of 400 senior decision-makers include regulation, data privacy, talent shortages and rising development costs. Despite these hurdles, companies are exploring new markets, launching new products, and leveraging automation for efficiency. Our report offers invaluable insights to help you navigate the complex life sciences landscape with confidence. Download a copy of your free report here: https://ow.ly/zfc750Sr3JT #LifeSciences #Innovation #Biotech #Pharma #RiskManagement #WTWDirectandFac